Physician profile
Malabika Dey
NPI 1629000153
$2,410.54
in general payments reported to CMS, 2019-2025
17 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.86 · 2020: $68.71 · 2022: $172 · 2023: $477 · 2024: $352 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,891 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,890.84 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.56 | 2022-2025 | |
| Lilly USA, LLC | $324.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $309.92 | 2024-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $300.18 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $216.42 | 2023-2025 | Veozah |
| Pfizer INC. | $186.60 | 2024-2025 | |
| Alkermes, INC. | $132.33 | 2023-2024 | Aristada, Aristada Initio, Lybalvi |
| Sumitomo Pharma America, INC. | $92.57 | 2024-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $68.71 | 2020 | |
| Aimmune Therapeutics, INC. | $64.50 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $59.01 | 2024-2025 | Ibsrela |
| Amgen INC. | $36.04 | 2023-2024 | Repatha, Otezla |
| Lundbeck LLC | $21.59 | 2025 | Rexulti |
| Abbott Laboratories | $19.34 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.28 | 2024 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18.10 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.68 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malabika Dey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.